Aashirwad Pharma International Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Aashirwad Pharma International Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $50.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aashirwad Pharma International Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $50.8K Trade | TransData Nexus

Aashirwad Pharma International Private Limited

Indian Pharmaceutical Exporter · Brand Names & OTC Products Specialist · $50.8K Total Trade · DGFT Verified

Aashirwad Pharma International Private Limited is an Indian pharmaceutical exporter with a total trade value of $50.8K across 3 products in 1 therapeutic categories. Based on 74 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Iodex ($31.2K), Brufen ($12.8K), Savlon ($6.7K).

Aashirwad Pharma International Private Limited — Export Portfolio & Destination Treemap

Aashirwad Pharma International Private Limited pharmaceutical export portfolio — 3 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Aashirwad Pharma International Private Limited? — Company Overview & Market Position

Aashirwad Pharma International Private Limited (APIPL), formerly known as Aashirwad Exports, is a merchant exporter and wholesaler specializing in generic and branded pharmaceutical formulations. Established in 2013, the company is headquartered in Pune, Maharashtra, India. Incorporated on April 9, 2021, under the Corporate Identification Number (CIN) U51909PN2021PTC200187, APIPL operates as a private limited company with an authorized capital of ₹500,000 and a paid-up capital of ₹100,000. The company's registered address is Plot No. 24, Vishrambaug Society, Senapati Bapat Road, Pune 411016, Maharashtra, India. APIPL is a registered micro-enterprise under the MSMED Act, 2006, and is a member of PHARMAEXCIL India, APEDA, and the Federation of Pharma Merchant Exports (FPME).

What Does Aashirwad Pharma International Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Iodex$31.2K 2Brufen$12.8K

Product Portfolio — Top 3 by Export Value

Aashirwad Pharma International Private Limited exports 3 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Iodex	Brand Names & OTC Products	$31.2K	30	0.5%	9
2	Brufen	Brand Names & OTC Products	$12.8K	27	0.3%	9
3	Savlon	Brand Names & OTC Products	$6.7K	17	7.3%	4

Aashirwad Pharma International Private Limited exports 3 pharmaceutical products across 1 therapeutic categories with a total export value of $50.8K. The top category is Brand Names & OTC Products (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Aashirwad Pharma International Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

APIPL operates as a merchant exporter and wholesaler, sourcing pharmaceutical products from various manufacturers rather than maintaining its own manufacturing facilities. The company collaborates with established pharmaceutical manufacturers to offer a diverse range of products, including generic and branded formulations. This approach allows APIPL to provide a wide array of pharmaceutical products without the overhead associated with owning manufacturing plants.

3Key Leadership

The leadership team of Aashirwad Pharma International Private Limited comprises:

Nikhil Suhas Angal: Director
Shruti Nikhil Angal: Director

Both directors have been associated with the company since its incorporation on April 9, 2021.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Aashirwad Pharma International Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

APIPL's export activities are primarily focused on markets in the Caribbean Islands, Northern America, Southeast Asia, Africa, and South America. The company has not publicly disclosed specific regulatory filings, approvals, or market access statuses in the United States, European Union, United Kingdom, Australia, or Japan. Given the absence of detailed information, it is advisable for potential partners to conduct thorough due diligence to assess APIPL's compliance with regulatory requirements in these regions.

2Emerging Markets

APIPL has established a presence in emerging markets across Africa, Latin America, and Southeast Asia. The company has not publicly disclosed specific information regarding WHO prequalification or other certifications that would facilitate access to these markets. Prospective partners should verify APIPL's compliance with local regulatory standards and certifications to ensure market access.

3Geographic Strategy

APIPL's export strategy demonstrates a diversified approach, targeting multiple regions including the Caribbean Islands, Northern America, Southeast Asia, Africa, and South America. This diversification helps mitigate concentration risk and positions the company to leverage growth opportunities across various markets. However, the lack of detailed information on specific market shares and competitive positioning makes it challenging to fully assess the strategic direction and effectiveness of this approach.

Aashirwad Pharma International Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

APIPL has not publicly disclosed information regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. Given the absence of such disclosures, it is recommended that potential partners conduct comprehensive due diligence to assess APIPL's compliance with FDA regulations and standards.

2WHO & EU GMP

APIPL has not publicly disclosed information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. Prospective partners should verify APIPL's compliance with these international quality standards to ensure product quality and safety.

3CDSCO & Indian Regulatory

APIPL has not publicly disclosed specific details about its compliance with the Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs). Given the absence of such information, it is advisable for potential partners to conduct thorough due diligence to assess APIPL's adherence to Indian regulatory requirements.

Aashirwad Pharma International Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

APIPL operates in a competitive landscape with numerous pharmaceutical exporters targeting similar markets. The company's top three exported products are:

Savlon: $7K in exports, ranked #4 with a 7.3% market share.
Iodex: $31K in exports, ranked #9 with a 0.5% market share.
Brufen: $13K in exports, ranked #9 with a 0.3% market share.

These figures indicate that while APIPL has a presence in the market, its share is relatively modest compared to larger competitors. The company's portfolio concentration, with the top three products accounting for 100% of exports, suggests a lack of diversification, which could pose risks if market dynamics change.

2Key Differentiators

APIPL's key differentiators include its focus on high-quality, cost-effective pharmaceutical formulations and its commitment to reliable service and honest relationships with customers. The company's membership in industry associations such as PHARMAEXCIL India, APEDA, and FPME reflects its engagement with the pharmaceutical export community. However, the lack of detailed information on certifications and regulatory approvals may limit its appeal to certain international markets.

Buyer Due Diligence Brief — Evaluating Aashirwad Pharma International Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

APIPL's track record as a merchant exporter and wholesaler indicates experience in sourcing and distributing pharmaceutical products. The company's export volume of $51K across 74 shipments, with a portfolio concentrated in three products, suggests a niche focus. Reliability indicators are not publicly disclosed, so potential partners should conduct thorough due diligence to assess APIPL's consistency and dependability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm that APIPL's manufacturing partners are registered with the FDA.
WHO-GMP Certification: Ensure that APIPL's products are manufactured in facilities compliant with WHO Good Manufacturing Practices.
EU GMP Certification: Verify that APIPL's products meet EU Good Manufacturing Practice standards.

Frequently Asked Questions — Aashirwad Pharma International Private Limited

How many pharmaceutical products does Aashirwad Pharma International Private Limited export from India?

Aashirwad Pharma International Private Limited exports 3 pharmaceutical products across 1 therapeutic categories. The top exports are Iodex ($31.2K), Brufen ($12.8K), Savlon ($6.7K). Total export value is $50.8K.

What is Aashirwad Pharma International Private Limited's total pharmaceutical export value?

Aashirwad Pharma International Private Limited's total pharmaceutical export value is $50.8K, based on 74 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Aashirwad Pharma International Private Limited cover?

Aashirwad Pharma International Private Limited exports across 1 therapeutic categories. The largest are Brand Names & OTC Products (100.0%, 3 products).

Get Full Aashirwad Pharma International Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.